Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KAN-101 in Celiac Disease (ACES Study)
NCT05574010Phase 2Terminated
- Sponsor
- Anokion
- Start
- Nov 2022
- Primary completion
- Nov 2024
- Countries
- 3
01
Overview
A Phase 2 trial of KAN-101 in celiac disease, sponsored by Anokion. Started Nov 2022; status: terminated.
02
Drugs
KAN-101
03
Conditions
celiac disease
Beyond the preview
Go deeper on NCT05574010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05574010.